Physician profile
Mark Sukenik
NPI 1528069242
$6,157.90
in general payments reported to CMS, 2019-2025
21 companies · $1,479 in 2025
The $1,479 reported for 2025 was more than what 86% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $341 · 2020: $308 · 2021: $791 · 2022: $1,149 · 2023: $717 · 2024: $1,372 · 2025: $1,479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,568.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,568.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerin Medical INC. | $1,513.09 | 2019-2024 | |
| Optinose US, INC. | $1,020.57 | 2019-2025 | |
| Genzyme Corporation | $962.04 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $805.18 | 2021-2025 | Dupixent, Libtayo |
| Glaxosmithkline, LLC. | $499.12 | 2021-2025 | Nucala |
| Alk-Abello, INC | $437.47 | 2019-2022 | |
| Genentech USA, INC. | $174.56 | 2025 | Xolair |
| Intersect Ent, INC. | $148.99 | 2019-2021 | |
| Medtronic, INC. | $107.94 | 2024-2025 | Sinuva, Propel, Nuvent |
| Kaleo, INC. | $93.27 | 2020-2024 | Auvi-Q |
| Ars Pharmaceuticals Operations, INC. | $76.76 | 2025 | Neffy |
| Neurent Medical Limited | $70.86 | 2024-2025 | Neuromark Radiofrequency Console, Neuromark System, Neuromark Device |
| Merck Sharp & Dohme LLC | $42.63 | 2022-2023 | |
| Smith+Nephew, INC. | $38.22 | 2019-2020 | |
| Acclarent, INC | $37.10 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $32.62 | 2023-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Stryker Corporation | $29.75 | 2025 | Scopis Ent |
| Paratek Pharmaceuticals, INC. | $18.90 | 2025 | Xhance |
| Resmed Corp | $18.55 | 2022 | |
| Olympus America INC. | $16.00 | 2023 | Rhino-Laryngo Videoscope |
| Ambu INC. | $14.28 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Sukenik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.